Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

ConclusionSaracatinib did not improve outcomes in post-menopausal women with metastatic breast cancer. There was no observed beneficial effect on bone metastases.CRUKE/11/023, ISRCTN23804370.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research